« Previous
Next »
Titles
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- Part D plans generally include drugs commonly used by dual eligibles: 20171
- Part D plans generally include drugs commonly used by dual eligibles: 20181
- Part D plans generally include drugs commonly used by dual eligibles: 20191
- Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers1
- Snapshots of recent state initiatives in Medicaid prescription drug cost control1
- Some Medicare Part D beneficiaries face avoidable extra steps that can delay or prevent access to prescribed drugs1
- State Pharmacy Assistance Programs vs. Medicare prescription drug plans: how do they contain rising costs?1
- Strategic analysis & intelligence (SAI) report: the tier 4 phenomenon : shifting the high cost of drugs to consumers1
- Summary of recent and proposed changes to Medicare prescription drug coverage and reimbursement1
- The Medicare drug benefit: options for low-income Californians in 20081
- Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal1
- Veterans affairs contracting: improvements in buying medical and surgical supplies could yield cost savings and efficiency : testimony before the Committee on Veterans' Affairs, House of Representatives1
- What can the United States learn from pharmaceutical spending controls in France?1